Published in Cardiovascular Business Week, September 11th, 2007
The Company plans to announce five-year results from the TAXUS II clinical trial. The data are expected to build on the strong body of clinical evidence supporting the continued efficacy and long-term safety profile of the TAXUS(R) Paclitaxel-Eluting Stent System. In addition, the Company will announce partial one-year data from Phases II and III of the OLYMPIA registry, designed to study real-world outcomes of its TAXUS(R) Liberte(TM)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.